First human trial of KW39 slotted-tube stents: for percutaneous coronary intervention
- PMID: 22163123
- PMCID: PMC3231518
First human trial of KW39 slotted-tube stents: for percutaneous coronary intervention
Abstract
The KW39 stent is a balloon-expandable, stainless-steel, slotted-tube stent, newly designed to adjust to the shape of the coronary arteries. We evaluated the clinical efficacy and safety of KW39 stent-based percutaneous coronary interventions in human native coronary arteries. A total of 105 patients (110 lesions), with a diagnosis of stable angina, acute coronary syndrome, or asymptomatic myocardial ischemia, were included in this prospective study. The primary endpoint was the target-lesion revascularization rate at the conclusion of a 6-month follow-up period. The secondary endpoints were the rates of technical and procedural success and the rate of major adverse cardiac events (defined as cardiac death, myocardial infarction, and target-lesion revascularization) in the course of the 6 months after stent placement. The 6-month target-lesion revascularization rate was 8.6%. The KW39 stent was highly satisfactory in regard to all secondary endpoint comparisons. Binary (>50%) in-stent restenosis was observed in 22 of 110 lesions (20%). The mean diameter stenosis at 6 months after percutaneous coronary intervention was 35.1% ± 14.4%, and the mean late lumen loss was 1.06 ± 0.48 mm. Stepwise multivariate analysis showed probable causal associations between adverse local environments for stent implantation and the subsequent need for target-lesion revascularization. We conclude that KW39 stent implantation was technically feasible and clinically safe in the patient population that we studied. The results of the safety endpoints, including cardiac death and acute myocardial infarction, were acceptable.
Keywords: Coronary interventions, percutaneous; coronary restenosis/prevention & control; equipment design; equipment safety; humans; pliability; prospective studies; prosthesis design; stents; stress, mechanical; treatment outcome.
Figures


Similar articles
-
Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).JACC Cardiovasc Interv. 2011 May;4(5):543-50. doi: 10.1016/j.jcin.2010.12.014. JACC Cardiovasc Interv. 2011. PMID: 21596327 Clinical Trial.
-
2-year results of the AUTAX (Austrian Multivessel TAXUS-Stent) registry beyond the SYNTAX (synergy between percutaneous coronary intervention with TAXUS and cardiac surgery) study.JACC Cardiovasc Interv. 2009 Aug;2(8):718-27. doi: 10.1016/j.jcin.2009.05.019. JACC Cardiovasc Interv. 2009. PMID: 19695539 Clinical Trial.
-
Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial.Circ Cardiovasc Interv. 2012 Oct;5(5):633-40. doi: 10.1161/CIRCINTERVENTIONS.111.965673. Epub 2012 Oct 9. Circ Cardiovasc Interv. 2012. PMID: 23048051 Clinical Trial.
-
Long-term clinical safety and efficacy of drug-coated balloon in the treatment of in-stent restenosis: A meta-analysis and systematic review.Catheter Cardiovasc Interv. 2020 Aug;96(2):E129-E141. doi: 10.1002/ccd.28572. Epub 2019 Nov 12. Catheter Cardiovasc Interv. 2020. PMID: 31714010
-
Optimization of stent deployment by intravascular ultrasound.Korean J Intern Med. 2012 Mar;27(1):30-8. doi: 10.3904/kjim.2012.27.1.30. Epub 2012 Feb 28. Korean J Intern Med. 2012. PMID: 22403496 Free PMC article. Review.
Cited by
-
Swine model of in-stent stenosis in the iliac artery evaluating the serial time course.Exp Anim. 2018 Nov 1;67(4):501-508. doi: 10.1538/expanim.18-0027. Epub 2018 Aug 1. Exp Anim. 2018. PMID: 30068792 Free PMC article.
References
-
- Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356(10):998–1008. - PubMed
-
- Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009;119(25):3198–206. - PubMed
-
- Greenhalgh J, Hockenhull J, Rao N, Dundar Y, Dickson RC, Bagust A. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev 2010;(5):CD004587. - PubMed
-
- Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004;364(9434):583–91. - PubMed
-
- Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006;27(23):2784–814. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical